Estrogenized HSA induced high-affinity autoantibodies in breast cancer - Novel biomarker for early detection

Subuhi Sherwani; Mohd Wajid Ali Khan; Wahid Ali Khan; Saravanan Rajendrasozhan; Khalid Al-Motair; Hamda Khan; Saheem Ahmad

doi:10.3389/fonc.2024.1493320

Estrogenized HSA induced high-affinity autoantibodies in breast cancer - Novel biomarker for early detection

Front Oncol. 2024 Nov 27:14:1493320. doi: 10.3389/fonc.2024.1493320. eCollection 2024.

Authors

Subuhi Sherwani^{1

2}, Mohd Wajid Ali Khan^{2

3}, Wahid Ali Khan⁴, Saravanan Rajendrasozhan^{2

3}, Khalid Al-Motair², Hamda Khan^{5

6}, Saheem Ahmad^{2

7}

Affiliations

¹ Department of Biology, College of Science, University of Hail, Hail, Saudi Arabia.
² Medical and Diagnostic Research Center, University of Hail, Hail, Saudi Arabia.
³ Department of Chemistry, College of Science, University of Hail, Hail, Saudi Arabia.
⁴ Department of Clinical Biochemistry, College of Medicine, King Khalid University, Abha, Saudi Arabia.
⁵ Department of Biochemistry, J.N. Medical College, Aligarh Muslim University, Aligarh, India.
⁶ IIRC-1, Department of Biosciences, Integral University, Lucknow, India.
⁷ Department of Medical Laboratories, College of Applied Medical Sciences, University of Hail, Hail, Saudi Arabia.

Abstract

Objective: Breast cancer (BC) is the second most prevalent cancer worldwide. Estrogen has been increasingly recognized as a major contributor to the development of BC, playing a more critical role than previously understood. Estrogen derived nucleic acid and protein adducts have been shown to play significant roles in BC development and progression. However, the alterations in molecular mechanism(s) and immune pathways arising as a result of estrogenization still remain elusive.

Patients and methods: 4-hydroxyestradiol (4-OHE₂) was used for adduct formation with protein human serum albumin (HSA) (4-OHE₂-HSA). The affinity of antibodies for 4-OHE₂-HSA was evaluated in breast cancer patients. Immunoassays (direct binding ELISA, inhibition ELISA, and quantitative precipitin titration assay) were used to assess autoantibodies against estrogenized HSA in BC patients (n = 85) and healthy controls (n = 45).

Results: Estrogenization of HSA altered both its structure and function and compromised its interactions with various HSA-binding proteins. BC patients demonstrated high-affinity antibodies against 4-OHE₂-HSA as compared to HSA (p < 0.05). Additionally, cytokines Interleukin (IL)-1, IL-6 and tumor necrosis factor-alpha (TNF-α) were significantly elevated in BC patients as compared to the control group. Several factors, such as chemotherapy, estrogen receptors (ERs), and combination of surgery and chemotherapy, influenced the production of antibodies in cancer patients. The affinity constant for estrogenized HSA was 1.31 × 10^-7 M, while for HSA and 4-OHE₂, it was 1.68 × 10^-6 M and 1.36 × 10^-6 M, respectively.

Conclusions: Estrogenized HSA is highly immunogenic, resulting in functional alterations. High affinity antibodies were detected in BC patients against 4-OHE₂-HSA. Consequently, 4-OHE₂-HSA may serve as a novel molecular target for potential cancer therapeutics. Furthermore, autoantibodies against 4-OHE₂-HSA could serve as a potential biomarker for early detection of BC.

Keywords: BC biomarker; ELISA; HSA; autoantibodies; breast cancer; estrogen; molecular target.

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This research was funded by the Scientific Research Deanship at the University of Hail-Saudi Arabia through project number MDR-22017.